摘要
肝细胞癌是临床上最常见的消化系统恶性肿瘤之一,是导致癌症相关死亡的第二大病因。肝细胞癌的发生机制比较复杂,临床治疗手段有限,预后不佳。适配体的筛选和建立,可用于分子生物学细胞检测、影像分析以及靶向治疗,是肝细胞癌诊治新的希望。适配体相关研究从肝细胞癌细胞的检测、分子标志物检测出发,形成了良好的开端,为进一步实现干扰信号通路、介导基因、靶向治疗,提供了新的方向。本综述兼顾了肝细胞癌的临床诊断现状,重点阐述了适配体技术原理及其在肝细胞癌诊断中的研究进展。
Hepatocellular carcinoma(HCC) is one of the most common malignancies in digestive system and the second leading cause of cancer-related death. It has complicated pathogenesis, limited clinical treatments and poor prognosis. The screening and establishment of Aptamers can be used for molecular biological cell detection, image analysis and targeted therapy so as to be a new hope for the diagnosis and treatment of hepatocellular carcinoma. Relevant studies have made a good start from the detection of hepatocellular carcinoma cells and molecular markers, providing a new direction for the further progression of interfering signal pathways, mediating genes and targeted therapy.This review concentrates on the clinical diagnosis of hepatocellular carcinoma, the principle of Aptamer experiment and its progress in the diagnosis of hepatocellular carcinoma.
引文
[1] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015 [J].CA Cancer J Clin,2016,66(2):115-132.
[2] Llovet JM,Zucman-Rossi J,Pikarsky E,et al.Hepatocellular carcinoma[J].Nat Rev Dis Primers,2016(2):16018.
[3] Schmidt S,Follmann M,Malek N,et al.Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma [J].J Gastroenterol Hepatol,2011,26(12):1779-1786.
[4] Schulze K,Imbeaud S,Letouzé E,et al.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J].Nat Genet,2015,47(5):505-511.
[5] European association for the study of the liver,european organisation for research and treatment of cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma [J].J Hepatol,2012,56(4):908-943.
[6] Verslype C,Rosmorduc O,Rougier P,et al.Hepatocellular carcinoma:ESMO-ESDO clinical practice guidelines for diagnosis,treatment and follow-up [J].Ann Oncol,2012,23(Suppl7):41-48.
[7] 黄天从,李新丰,刘德鑫,等.甲胎蛋白异质体在老年肝癌诊断与肝动脉化疗栓塞治疗中的临床意义[J/CD].中华诊断学电子杂志,2017,5(4):243-24
[8] 周文瑞,李新丰,林奇忆,等.血清甲胎蛋白异质体、高尔基体糖蛋白-73及甲胎蛋白检测在老年人原发性肝癌的诊断价值[J/CD].中华诊断学电子杂志,2016,4(4):222-225.
[9] Yu SJ.A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world:2010-2016 [J].Clin Mol Hepatol,2016,22(1):7-17.
[10] Marrero JA,Feng Z,Wang Y,et al.Alpha-fetoprotein,des-gamma carboxyprothrombin,and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma [J].Gastroenterology,2009,137(1):110-118.
[11] Yu B,Yang X,Xu Y,et al.Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas [J].J Hepatol,2009,50(5):948-957.
[12] Shen Q,Fan J,Yang XR,et al.Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma:a large-scale,multicentre study [J].Lancet Oncol,2012,13(8):817-826.
[13] Lin XJ,Chong Y,Guo ZW,et al.A serum microRNA classifier for early detection of hepatocellular carcinoma:a multicentre,retrospective,longitudinal biomarker identification study with a nested case-control study [J].Lancet Oncol,2015,16(7):804-815.
[14] Alix-Panabières C,Pantel K.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy [J].Cancer Discov,2016,6(5):479-491.
[15] Zhou J,Huang A,Yang XR.Liquid biopsy and its potential for management of hepatocellular carcinoma [J].J Gastrointest Cancer,2016,47(2):157-167.
[16] Sun YF,Xu Y,Yang XR,et al.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection [J].Hepatology,2013,57(4):1458-1468.
[17] Huang A,Zhang X,Zhou SL,et al.Plasma circulating cellfree DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma [J].J Cancer,2016,7(13):1798-1803.
[18] Tuerk C,Gold L.Systematic evolution of ligands by exponential enrichment:RNA ligands to bacteriophage T4 DNA polymerase[J].Science,1990,249(4968):505-510.
[19] Ellington AD,Szostak JW.In vitro selection of RNA molecules that bind specific ligands[J].Nature,1990,346(6287):818-822.
[20] Ahmadyousefi Y,Malih S,Mirzaee Y,et al.Nucleic acid Aptamers in diagnosis of colorectal cancer[J].Biochimie,2019(156):1-11.
[21] Lu B,Wang J,Zhang J,et al.Screening and verification of ssDNA Aptamers targeting human hepatocellular carcinoma[J].Acta Biochim Biophys Sin (Shanghai),2014,46(2):128-135.
[22] Chen H,Yuan CH,Yang YF,et al.Subtractive Cell-SELEX selection of DNA Aptamers binding specifically and selectively to hepatocellular carcinoma cells with high metastatic potential[J].Biomed Res Int,2016 (2016):5735869.
[23] Wang FB,Rong Y,Fang M,et al.Recognition and capture of metastatic hepatocellular carcinoma cells using Aptamer-conjugated quantum dots and magnetic particles[J].Biomaterials,2013,34(15):3816-3827.
[24] Du J,Hong J,Xu C,et al.Screening and Identification of ssDNA Aptamer for Human GP73[J].Biomed Res Int,2015 (2015):610281.
[25] Dong L,Tan Q,Ye W,et al.Screening and identifying a novel ssDNA Aptamer against alpha-fetoprotein using CE-SELEX[J].Sci Rep,2015(5):15552.
[26] Lee KA,Ahn JY,Lee SH,et al.Aptamer-based sandwich assay and its clinical outlooks for detecting lipocalin-2 in hepatocellular carcinoma (HCC)[J].Sci Rep,2015(5):10897.
